ABSTRACT
Background: COVID-19, which occurred at the end of December 2019, has evolved into a global public health threat. COVID-19’s high infectivity and mortality prompt governments and scientific community to respond quickly to the outbreak of the pandemic. The application of personal protective equipment (PPE) is of great significance in overcoming the epidemic situation. Although there were many studies about PPE and COVID-19, there is no study about bibliometric analysis of these studies. This study aims to provide a general overview of studies on PPE and COVID-19. Methods: On October 07, 2021, the Web of Science (WOS) Core Collection database was used to identify documents on PPE and COVID-19. HistCite and VOSviewer softwares were used for citation analysis and visualization mapping. Results: A total of 1462 documents authored by 6993 authors and published in 750 journals were included in the final analysis. The most prolific author was Macintyre CR. The USA was the most productive country with 463 published documents. The leading journal was Plos One. Network visualization map showed that USA was the largest international collaboration network. The keyword “COVID-19” had the strongest total link strengths (TLS) and largest number of occurrences. The New England Journal of Medicine was the leading source with highest TLS. The University of Toronto had the highest number of links and the highest TLS. Conclusions: The bibliometric analysis of PPE and COVID-19 provides an overall perspective, and the appreciation and study of these influential publications are very useful for future research.
Subject(s)
COVID-19ABSTRACT
Mesenchymal stem cells (MSCs) therapy is considered one of the most promising treatments in the context of the coronavirus disease 2019 (COVID-19) pandemic. However, the safety and effectiveness of MSCs in the treatment of COVID-19-associated pneumonia patients need to be systematically reviewed and analyzed. Two independent researchers searched for the relevant studies published between October 2019 and April 2021 in PubMed, Embase, Cochrane Library, WAN FANG, and CNKI databases. A total of 22 studies involving 371 patients were included in the present study. MSCs were administered in 247 participants, and MSCs were allogeneic from umbilical cord, adipose tissue, menstrual blood, placenta, Whartons jelly, or unreported sources. Combined results found that MSCs group significantly reduced the incidence of adverse events (OR = 0.43, 95%CI. = 0.22[~]0.84, P = 0.01) and mortality (OR = 0.17, 95%CI. = 0.06[~]0.49, P < 0.01), and the difference compared with control group was statistically significant. No MSCs treat-related serious adverse events were reported. The lung function and radiographic outcomes, and biomarker levels of inflammation and immunity all showed improvement trends. Therefore, MSCs therapy is an effective and safe method in the treatment of COVID-19-associated pneumonia and shows advantages in less adverse events and mortality. However, a standard and effective MSCs treatment program needs to be developed.